These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20563590)

  • 21. Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
    Nelson RC; Silva Merea V; Tierney WS; Milstein C; Benninger MS; Bryson PC
    Laryngoscope; 2019 Jun; 129(6):1433-1437. PubMed ID: 30588631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia.
    Epstein R; Stygall J; Newman S
    Disabil Rehabil; 1997 Jan; 19(1):20-5. PubMed ID: 9021281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applied botulinum neurotoxin injection in a patient with dementia to reduce hypersalivation.
    Yuruyen M; Gokturk A; Yavuzer H; Döventas A; Erdincler DS
    Geriatr Gerontol Int; 2017 Jun; 17(6):1028-1029. PubMed ID: 28635110
    [No Abstract]   [Full Text] [Related]  

  • 25. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
    Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Singer's dystonia: first report of a variant of spasmodic dysphonia.
    Chitkara A; Meyer T; Keidar A; Blitzer A
    Ann Otol Rhinol Laryngol; 2006 Feb; 115(2):89-92. PubMed ID: 16514788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report.
    Warrick P; Dromey C; Irish J; Durkin L
    J Voice; 2000 Sep; 14(3):410-21. PubMed ID: 11021508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated.
    Restivo DA; Panebianco M; Casabona A; Lanza S; Marchese-Ragona R; Patti F; Masiero S; Biondi A; Quartarone A
    Toxins (Basel); 2018 Jan; 10(2):. PubMed ID: 29382036
    [No Abstract]   [Full Text] [Related]  

  • 30. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics.
    Samotus O; Kumar N; Rizek P; Jog M
    Can J Neurol Sci; 2018 Jan; 45(1):11-22. PubMed ID: 29157315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders].
    García Ron A; Miranda MC; Garriga Braun C; Jensen Verón J; Torrens Martinez J; Diez Hanbino MP
    An Pediatr (Barc); 2012 Oct; 77(4):289-91. PubMed ID: 22652186
    [No Abstract]   [Full Text] [Related]  

  • 34. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome.
    Laccourreye O; Akl E; Gutierrez-Fonseca R; Garcia D; Brasnu D; Bonan B
    Arch Otolaryngol Head Neck Surg; 1999 Mar; 125(3):283-6. PubMed ID: 10190799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey's syndrome).
    Hartl DM; Julieron M; LeRidant AM; Janot F; Marandas P; Travagli JP
    J Laryngol Otol; 2008 Oct; 122(10):1100-4. PubMed ID: 18289458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the current uses of Botox for dentally-related procedures.
    Bhogal PS; Hutton A; Monaghan A
    Dent Update; 2006 Apr; 33(3):165-8. PubMed ID: 16700273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?
    Tiigimäe-Saar J; Taba P; Tamme T
    Clin Oral Investig; 2017 Apr; 21(3):795-800. PubMed ID: 27114092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum Toxin, a Drug with Potential Interest for Dentists-An Introduction.
    Bakke M
    Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].
    Svetel M; Vasić M; Tomić G; Stanković P; Stojanović M; Dragasević N; Dergenc R; Vukasinović M; Pekmezović T; Petrović I; Kostić V
    Vojnosanit Pregl; 2007 Oct; 64(10):671-5. PubMed ID: 18041568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.